<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="is properly cited. Abstract At the moment, developing new broad-spectrum" exact="influenza" post="vaccines which would help avoid annual changes in a"/>
 <result pre="urgency. In addition, developing new vaccines based on highly conserved" exact="influenza" post="virus proteins could allow us to better prepare for"/>
 <result pre="a key aspect of the characterization of the effectiveness of" exact="influenza" post="vaccines. In the development of new broad-spectrum influenza vaccines,"/>
 <result pre="effectiveness of influenza vaccines. In the development of new broad-spectrum" exact="influenza" post="vaccines, it is important to study the mechanisms of"/>
 <result pre="antibody-dependent cellular phagocytosis (ADCP), and antibody-mediated complement-dependent cytotoxicity (CDC). The" exact="influenza" post="virus antigens that trigger these reactions are hemagglutinin (HA)"/>
 <result pre="and to the stem domain of hemagglutinin (HA) of the" exact="influenza" post="virus are considered. influenza virus broad-spectrum influenza vaccine antibody-dependent"/>
 <result pre="domain of hemagglutinin (HA) of the influenza virus are considered." exact="influenza" post="virus broad-spectrum influenza vaccine antibody-dependent cellular cytotoxicity antibody-dependent cellular"/>
 <result pre="(HA) of the influenza virus are considered. influenza virus broad-spectrum" exact="influenza" post="vaccine antibody-dependent cellular cytotoxicity antibody-dependent cellular phagocytosis antibody-mediated complement-dependent"/>
 <result pre="children and 5 to 10% of adults are infected with" exact="influenza" post="annually in the world and 250 to 500 thousand"/>
 <result pre="to 500 thousand people die from severe complications of the" exact="influenza" post="infection. In pandemics, the extent of complications and mortality"/>
 <result pre="various sources, around 50 to 100 million people died from" exact="influenza" post="during the 1918–1919 flu pandemic [1]. The most potent"/>
 <result pre="flu pandemic [1]. The most potent protective measure against the" exact="influenza" post="infection and its spread is vaccination. Modern influenza vaccines,"/>
 <result pre="against the influenza infection and its spread is vaccination. Modern" exact="influenza" post="vaccines, as a rule, induce the formation of antibodies"/>
 <result pre="as a rule, induce the formation of antibodies to the" exact="influenza" post="HA and NA surface antigens. The surface proteins of"/>
 <result pre="HA and NA surface antigens. The surface proteins of the" exact="influenza" post="virus undergo constant antigenic drift. Therefore, annual renewal of"/>
 <result pre="is required [2]. To date, the development of new broad-spectrum" exact="influenza" post="vaccines which would help avoid the necessity of annual"/>
 <result pre="addition, the creation of new vaccines based on highly conserved" exact="influenza" post="virus proteins would allow us to better prepare for"/>
 <result pre="damage they cause. The key to evaluating the effectiveness of" exact="influenza" post="vaccines is to determine the level of humoral response"/>
 <result pre="viral infection and undergird the protective mechanisms of all the" exact="influenza" post="vaccines available to date [3]. Most virus-neutralizing antibodies bind"/>
 <result pre="antibodies to cells that have been previously infected with the" exact="influenza" post="virus [7]. Fig. 1 Mechanisms of action of anti-influenza"/>
 <result pre="[7]. Fig. 1 Mechanisms of action of anti-influenza antibodies. The" exact="influenza" post="virus enters the body through respiratory tract mucosa, where"/>
 <result pre="the mucous layer (a). After penetrating the mucous layer, the" exact="influenza" post="virus binds to the sialic acids on the surface"/>
 <result pre="and enters the cell by endocytosis. Neutralizing antibodies bind to" exact="influenza" post="HA and block this process (b).The endosomes of the"/>
 <result pre="complement system (g) Antibodies against various conserved antigens of the" exact="influenza" post="virus (such as NP, M1, M2) are generally non-neutralizing"/>
 <result pre="evaluating the level of such antibodies after immunization with new" exact="influenza" post="vaccines, is relevant for the development of novel broad-spectrum"/>
 <result pre="influenza vaccines, is relevant for the development of novel broad-spectrum" exact="influenza" post="vaccines. ANTIBODIES TO CONSERVED ANTIGENS OF THE INFLUENZA VIRUS"/>
 <result pre="ANTIBODY-MEDIATED COMPLEMENT-DEPENDENT CYTOTOXICITY The ability of antibodies to neutralize the" exact="influenza" post="virus has traditionally been considered the most important mechanism"/>
 <result pre="cellular phagocytosis (ADCP), and antibody-mediated complement-dependent cytotoxicity (CDC) [8]. The" exact="influenza" post="virus antigens that trigger these reactions are HA, NA,"/>
 <result pre="antibody-dependent cellular cytotoxicity (ADCC) in a cell infected with an" exact="influenza" post="virus. IgG binds to the viral antigens on the"/>
 <result pre="is one of the most represented surface proteins of the" exact="influenza" post="virus. For instance, it has been shown that antibodies"/>
 <result pre="against the conserved HA stem protect mice from a lethal" exact="influenza" post="infection through a mechanism that involves an interaction with"/>
 <result pre="interaction with FcγR [11]. Furthermore, re-infection of macaques with the" exact="influenza" post="virus has led to a rapid appearance of ADCC"/>
 <result pre="viruses close to the strain that caused the 2009 swine" exact="influenza" post="pandemic and who retained a significant amount of titers"/>
 <result pre="but had no neutralizing antibodies were protected from the pandemic" exact="influenza" post="virus. Thus, non-neutralizing HA stem-specific antibodies capable of inducing"/>
 <result pre="are directly related to the level of protection against an" exact="influenza" post="virus [14]. In addition, according to published data, vaccines"/>
 <result pre="[14]. In addition, according to published data, vaccines against seasonal" exact="influenza" post="viruses weakly induce the production of antibodies that can"/>
 <result pre="over a lifetime as a result of re-infection with various" exact="influenza" post="virus strains [15]. Using a panel of 13 monoclonal"/>
 <result pre="[15]. Using a panel of 13 monoclonal antibodies to the" exact="influenza" post="virus HA protein (both neutralizing and non-neutralizing ones, both"/>
 <result pre="not only certain HA-specific antibodies, but also antibodies to other" exact="influenza" post="antigens exposed on the surface of an infected cell,"/>
 <result pre="amount of the antibody involved in the interaction with the" exact="influenza" post="virus. It should be noted that, during viral infection,"/>
 <result pre="(NP), also contribute to the ADCC response. For instance, the" exact="influenza" post="infection and vaccination induce the production of antibodies to"/>
 <result pre="involved in ADCC [17, 18]. It has been shown that" exact="influenza" post="virus NP is expressed on the surface of infected"/>
 <result pre="vaccination of laboratory mice with soluble recombinant NP of the" exact="influenza" post="A virus induces high titers of antibodies to NP"/>
 <result pre="vaccination reduced the manifestation of disease symptoms and decreased the" exact="influenza" post="virus titers in the lungs of the influenza-infected animals"/>
 <result pre="immunized mice to naive animals also provided protection against an" exact="influenza" post="infection [22]. Subsequent studies have demonstrated that the protective"/>
 <result pre="the protective effects of the serum of mice immunized with" exact="influenza" post="A recombinant NP upon passive transfer to animals with"/>
 <result pre="not infants) contains antibodies to various proteins of the H7N9" exact="influenza" post="A virus that are involved in the ADCC response,"/>
 <result pre="NA. The level of antibodies to NP of the seasonal" exact="influenza" post="A viruses that are involved in ADCC correlated with"/>
 <result pre="with the level of antibodies to NP of the H7N9" exact="influenza" post="A virus. Therefore, production of these antibodies that cross-react"/>
 <result pre="assumed to be triggered by vaccination and infection with seasonal" exact="influenza" post="A viruses [25]. The antibodies to influenza A virus"/>
 <result pre="infection with seasonal influenza A viruses [25]. The antibodies to" exact="influenza" post="A virus NP involved in ADCC were found in"/>
 <result pre="in ADCC were found in children vaccinated with seasonal inactivated" exact="influenza" post="virus vaccines. NP-specific antibodies that can interact with FcγRIIIa"/>
 <result pre="activation against virus-infected cells expressing NP [13, 26]. Another conserved" exact="influenza" post="protein found on the surface of infected cells is"/>
 <result pre="channel. Antibodies to this protein can protect mice from an" exact="influenza" post="virus infection in laboratory experiments. Moreover, in the immunization"/>
 <result pre="anti-M2e antibodies [28, 29]. The human monoclonal antibody against the" exact="influenza" post="A (Ab1-10) virus M2 protein was able to activate"/>
 <result pre="against both target cells expressing M2 and cells infected with" exact="influenza" post="[30]. Fig. 3 Evaluation of ADCC in the laboratory."/>
 <result pre="ADCC in the laboratory. (a) Evaluation of ADCC using immobilized" exact="influenza" post="virus antigens. Firstly, antigens are immobilized, washed, and incubated"/>
 <result pre="and interferon gamma are used). (b) Evaluation of ADCC using" exact="influenza" post="virus-infected cells or target cells expressing the major viral"/>
 <result pre="of the most important antibody-induced effector defense mechanisms against the" exact="influenza" post="virus. FcγR-/- mice have been shown to be highly"/>
 <result pre="FcγR-/- mice have been shown to be highly sensitive to" exact="influenza" post="even in the presence of influenza antibodies obtained from"/>
 <result pre="be highly sensitive to influenza even in the presence of" exact="influenza" post="antibodies obtained from FcγR+/+ mice. Moreover, the absence of"/>
 <result pre="some non-neutralizing human broad-spectrum monoclonal antibodies protect mice from an" exact="influenza" post="infection through Fc-mediated recruitment of effector cells, with the"/>
 <result pre="action of the antibodies binding to the ectodomain of the" exact="influenza" post="M2 ion channel. Respiratory tract epithelial cells infected with"/>
 <result pre="M2 ion channel. Respiratory tract epithelial cells infected with the" exact="influenza" post="A virus expose the HA, NA, and M2 viral"/>
 <result pre="experiments on protecting animals from infection with homologous and heterologous" exact="influenza" post="A virus strains [37]. Interestingly, the ability of alveolar"/>
 <result pre="alveolar macrophages to protect the lungs from damage during an" exact="influenza" post="infection is reduced in elderly mice [38]. In addition"/>
 <result pre="populations can also participate in the ADCP-mediated response to the" exact="influenza" post="virus. For instance, neutrophils, which are the largest in"/>
 <result pre="[40, 41]. A study of the ADCP mechanism in the" exact="influenza" post="infection showed that both macrophages and neutrophils are quickly"/>
 <result pre="in virus shedding [42]. It is assumed that each subsequent" exact="influenza" post="infection, as well as influenza vaccinations, slightly induces the"/>
 <result pre="is assumed that each subsequent influenza infection, as well as" exact="influenza" post="vaccinations, slightly induces the cross-reactive antibodies involved in ADCP,"/>
 <result pre="involved in ADCP, with their level increasing with each subsequent" exact="influenza" post="infection [17]. Various anti-influenza antibodies, including antibodies to the"/>
 <result pre="responsible for ADCP is studied as follows: target cells expressing" exact="influenza" post="antigens are labeled with an intravital dye, then the"/>
 <result pre="complement system is necessary to protect mice from a lethal" exact="influenza" post="infection [44]. In 1983, it was established that human"/>
 <result pre="established that human serum contains antibodies capable of neutralizing the" exact="influenza" post="virus by activating the classical complement pathway [45]. To"/>
 <result pre="classical complement pathway [45]. To date it is known that" exact="influenza" post="virions can activate both the classical and alternative complement"/>
 <result pre="virus-like particles carrying the M2e proteins of human, porcine, and" exact="avian influenza" post="A viruses, as well as virus-like particles carrying HA"/>
 <result pre="particles carrying the M2e proteins of human, porcine, and avian" exact="influenza" post="A viruses, as well as virus-like particles carrying HA"/>
 <result pre="as well as virus-like particles carrying HA of the H5-subtype" exact="influenza" post="A virus. It turned out that immunization with the"/>
 <result pre="M2e vaccine did not protect C3 knockout mice from the" exact="influenza" post="A viruses, while even low levels of antibodies to"/>
 <result pre="M2e protein were enough to protect wild-type animals from the" exact="influenza" post="A virus infection upon passive transfer. On the contrary,"/>
 <result pre="strain-specific neutralizing antibodies, were protected from infection with a homologous" exact="influenza" post="virus despite the low level of antibody response [47]."/>
 <result pre="Thus, one can state the ability of antibodies to the" exact="influenza" post="virus M2 ion channel to protect against influenza A"/>
 <result pre="to the influenza virus M2 ion channel to protect against" exact="influenza" post="A virus infection through the activation of the complement"/>
 <result pre="infected cells. For instance, vaccination with a seasonal trivalent inactivated" exact="influenza" post="vaccine led to an increase in the level of"/>
 <result pre="was not pronounced [48]. CDC-inducing antibodies were detected among both" exact="influenza" post="HA head-specific and stem-specific antibodies. Meanwhile, antibodies to the"/>
 <result pre="of action and were able to induce CDC against different" exact="influenza" post="A strains [49]. Antibodies of the IgG1 and IgM"/>
 <result pre="involved in CDC correlated with the protection against a seasonal" exact="influenza" post="virus in children [32]. The activity of antibodies in"/>
 <result pre="by the rate of death of target cells expressing the" exact="influenza" post="antigen or infected with an influenza virus in solutions"/>
 <result pre="target cells expressing the influenza antigen or infected with an" exact="influenza" post="virus in solutions containing complement components and antibodies. Cell"/>
 <result pre="serum of people who have been infected bind to different" exact="influenza" post="strains, providing ground for the development of broad-spectrum vaccines"/>
 <result pre="broad-spectrum vaccines based on this antigen [52]. Antibodies to the" exact="influenza" post="virus HA stem The HA stem is more conserved"/>
 <result pre="neutralizing HA stem-specific antibodies is detected in humans after an" exact="influenza" post="infection or vaccination, with the infection being more effective"/>
 <result pre="pseudotyped viral vectors [55]. The latter present chimeric viruses carrying" exact="influenza" post="virus surface antigens that do not contain any genetic"/>
 <result pre="pseudoviruses are usually derived from lentiviral vectors and the vesicular" exact="stomatitis" post="virus. They allow avoidance of highly pathogenic influenza strains"/>
 <result pre="the vesicular stomatitis virus. They allow avoidance of highly pathogenic" exact="influenza" post="strains when performing a neutralization reaction (which is especially"/>
 <result pre="stem-specific antibodies than the conventional neutralization assay [55]. Antibodies to" exact="influenza" post="virus neuraminidase Influenza virus neuraminidase is involved in various"/>
 <result pre="the sialylated glycans of another one [56]. Antibodies to the" exact="influenza" post="virus NA can interfere with any of these processes"/>
 <result pre="HA-specific antibodies, NA-specific antibodies can protect laboratory animals from an" exact="influenza" post="infection [57]. Moreover, the presence of NA-specific antibodies also"/>
 <result pre="presence of NA-specific antibodies also correlates with protection against an" exact="influenza" post="virus in humans. The titer of anti-NA antibody has"/>
 <result pre="The production of antibodies to neuraminidase is induced by an" exact="influenza" post="infection. However, their level is usually lower than that"/>
 <result pre="infection bind to a wide range of modern and historical" exact="influenza" post="strains, inhibit NA activity, and protect laboratory mice in"/>
 <result pre="of broad-spectrum vaccines that induce the formation of antibodies to" exact="influenza" post="NA exist. One of them is the creation of"/>
 <result pre="N7, N8, N9, and etc.) associated with human and zoonotic" exact="influenza" post="strains. It is also possible to include NA as"/>
 <result pre="NA as an additional antigen in vaccines based on conserved" exact="influenza" post="antigens: such as M2, NP, etc. [58]. ELISA is"/>
 <result pre="of these antibodies were considered. Antibodies can provide protection against" exact="influenza" post="via Fc-independent or Fc-dependent mechanisms. Fc-independent antibodies directly neutralize"/>
 <result pre="strain-specific, are mainly involved in the direct neutralization of the" exact="influenza" post="virus. As a rule, Fc-dependent antibodies are non-neutralizing but"/>
 <result pre="of the HA, NA, M2, or NP proteins of the" exact="influenza" post="virus, and most of them are broad-spectrum antibodies [11,"/>
 <result pre="of them are broad-spectrum antibodies [11, 21, 28, 58]. The" exact="influenza" post="vaccines currently being developed are aimed at generating an"/>
 <result pre="immune response not mainly to the conventional HA and NA" exact="influenza" post="antigens, but to various conserved viral antigens. When creating"/>
 <result pre="The traditional methods for assessing the humoral immune response to" exact="influenza" post="vaccines by hemagglutination and neutralization reactions will no longer"/>
 <result pre="that can provide protection against both seasonal and potentially pandemic" exact="influenza" post="virus strains. Abbreviations ADCC antibody-dependent cellular cytotoxicity ADCP antibody-dependent"/>
</results>
